NASDAQ:CUR

Neuralstem Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

$1.45

+0.11 (+8.21 %)

(As of 03/1/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.36

Now: $1.45▼

$1.50

50-Day Range

$0.67

MA: $1.06▼

$1.52

52-Week Range

$1.10

Now: $1.45▼

$13.78

Volume627,380 shs

Average Volume236,278 shs

Market Capitalization$3.05 million

P/E RatioN/A

Dividend YieldN/A

Beta1.81

Neuralstem (NASDAQ:CUR) Vs. AMGN, GILD, MRNA, BIIB, SGEN, and BNTX

Should you be buying CUR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Neuralstem, including Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), Seagen (SGEN), and BioNTech (BNTX).

Neuralstem vs. Amgen Stock

Amgen (NASDAQ:AMGN) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Amgen and Neuralstem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$23.36 billion	5.61	$7.84 billion	$14.82	15.32
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A

Amgen has higher revenue and earnings than Neuralstem.

Profitability

This table compares Amgen and Neuralstem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amgen	29.42%	95.55%	15.52%
Neuralstem	-39,417.64%	-170.51%	-110.16%

Volatility & Risk

Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Amgen and Neuralstem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	0	11	14	0	2.56
Neuralstem	0	0	0	0	N/A

Amgen presently has a consensus price target of $256.4091, indicating a potential upside of 12.94%. Given Amgen's higher probable upside, research analysts clearly believe Amgen is more favorable than Neuralstem.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Amgen beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Neuralstem vs. Gilead Sciences Stock

Gilead Sciences (NASDAQ:GILD) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Gilead Sciences and Neuralstem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$22.45 billion	3.49	$5.39 billion	$6.14	10.17
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A

Gilead Sciences has higher revenue and earnings than Neuralstem.

Profitability

This table compares Gilead Sciences and Neuralstem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	5.48%	37.77%	12.76%
Neuralstem	-39,417.64%	-170.51%	-110.16%

Volatility & Risk

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Gilead Sciences and Neuralstem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	1	12	12	0	2.44
Neuralstem	0	0	0	0	N/A

Gilead Sciences presently has a consensus price target of $96.0370, indicating a potential upside of 53.76%. Given Gilead Sciences' higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than Neuralstem.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gilead Sciences beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Neuralstem vs. Moderna Stock

Moderna (NASDAQ:MRNA) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Moderna and Neuralstem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$60.21 million	1,034.46	$-514,020,000.00	($1.55)	-101.55
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A

Neuralstem has lower revenue, but higher earnings than Moderna.

Profitability

This table compares Moderna and Neuralstem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-242.73%	-28.11%	-20.31%
Neuralstem	-39,417.64%	-170.51%	-110.16%

Volatility & Risk

Moderna has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Moderna and Neuralstem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	3	6	9	0	2.33
Neuralstem	0	0	0	0	N/A

Moderna presently has a consensus price target of $149.6471, indicating a potential downside of 4.93%. Given Moderna's higher probable upside, research analysts clearly believe Moderna is more favorable than Neuralstem.

Insider & Institutional Ownership

51.2% of Moderna shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 29.2% of Moderna shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Moderna beats Neuralstem on 9 of the 11 factors compared between the two stocks.

Neuralstem vs. Biogen Stock

Biogen (NASDAQ:BIIB) and Neuralstem (NASDAQ:CUR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Biogen and Neuralstem's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biogen	35.63%	51.00%	23.54%
Neuralstem	-39,417.64%	-170.51%	-110.16%

Analyst Ratings

This is a summary of recent ratings for Biogen and Neuralstem, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	5	15	12	0	2.22
Neuralstem	0	0	0	0	N/A

Biogen presently has a consensus price target of $304.4667, indicating a potential upside of 11.43%. Given Biogen's higher probable upside, research analysts clearly believe Biogen is more favorable than Neuralstem.

Insider & Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Biogen and Neuralstem's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$14.38 billion	2.90	$5.89 billion	$33.57	8.14
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A

Biogen has higher revenue and earnings than Neuralstem.

Volatility & Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Summary

Biogen beats Neuralstem on 8 of the 11 factors compared between the two stocks.

Neuralstem vs. Seagen Stock

Neuralstem (NASDAQ:CUR) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Neuralstem and Seagen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuralstem	-39,417.64%	-170.51%	-110.16%
Seagen	25.34%	20.46%	16.67%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuralstem and Seagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuralstem	0	0	0	0	N/A
Seagen	1	5	11	1	2.67

Seagen has a consensus price target of $188.4615, indicating a potential upside of 23.54%. Given Seagen's higher probable upside, analysts plainly believe Seagen is more favorable than Neuralstem.

Insider and Institutional Ownership

38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Comparatively, 31.1% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neuralstem and Seagen's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A
Seagen	$916.71 million	30.15	$-158,650,000.00	($1.33)	-114.70

Neuralstem has higher earnings, but lower revenue than Seagen.

Risk and Volatility

Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Summary

Seagen beats Neuralstem on 10 of the 12 factors compared between the two stocks.

Neuralstem vs. BioNTech Stock

Neuralstem (NASDAQ:CUR) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Neuralstem and BioNTech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuralstem	-39,417.64%	-170.51%	-110.16%
BioNTech	-250.12%	-66.72%	-41.73%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuralstem and BioNTech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuralstem	0	0	0	0	N/A
BioNTech	0	4	3	0	2.43

BioNTech has a consensus price target of $102.75, indicating a potential downside of 6.77%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Neuralstem.

Insider and Institutional Ownership

38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neuralstem and BioNTech's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuralstem	$260,000.00	11.71	$-4,930,000.00	N/A	N/A
BioNTech	$121.63 million	218.18	$-200,540,000.00	($0.95)	-116.01

Neuralstem has higher earnings, but lower revenue than BioNTech.

Risk and Volatility

Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500.

Summary

BioNTech beats Neuralstem on 7 of the 11 factors compared between the two stocks.